Advertisement

Topics

Collaboration announced for development of Parkinson’s treatment

07:38 EDT 1 Sep 2017 | EPM Magazine

A collaboration has been announced between AstraZeneca and Takeda Pharmaceutical Company for the development and commercialisation of an alpha-synuclein antibody, MEDI1341, as a potential treatment for Parkinson’s disease.

Original Article: Collaboration announced for development of Parkinson’s treatment

NEXT ARTICLE

More From BioPortfolio on "Collaboration announced for development of Parkinson’s treatment"

Quick Search
Advertisement
 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...